TLX Telix Pharmaceuticals Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 2007191 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · AUD | FY20222022-12-31 · AUD |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $803.79M | $516.55M | 502.55M | 160.10M |
| Cost of revenue | $377.36M | $180.39M | 188.16M | 65.17M |
| Gross profit | $426.44M | $336.16M | 314.39M | 94.93M |
| R&D expense | $171.25M | $127.93M | 128.54M | 80.69M |
| SG&A expense | $95.79M | $85.32M | 74.18M | 47.16M |
| Operating income | $29.78M | $55.18M | 15.84M | -91.93M |
| Interest expense | $181,000 | $64,000 | 148,000 | 46,000 |
| Pretax income | -$5.27M | $37.91M | 3.09M | -98.62M |
| Income tax | $1.86M | $4.23M | -2.12M | 5.46M |
| Net income | -$7.12M | $33.69M | 5.21M | -104.08M |
| EBITDA | $51.28M | $60.03M | 22.58M | -86.55M |
| EPS (basic) | -0.02 | 0.10 | 1.63 | -33.50 |
| EPS (diluted) | -0.02 | 0.10 | 1.61 | -33.50 |
| Weighted avg. shares (diluted) | 337.88M | 345.19M | 323.71M | 310.64M |
| Balance sheet | ||||
| Cash & equivalents | $141.87M | $440.00M | 123.24M | 116.33M |
| Receivables | $129.20M | $86.93M | 64.78M | — |
| Inventory | $37.08M | $23.62M | 17.31M | — |
| Current assets | $330.28M | $570.12M | 232.50M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $58.66M | $27.84M | 23.17M | 12.03M |
| Goodwill | $198.99M | $66.59M | — | — |
| Intangibles | $592.82M | $257.86M | 109.66M | 58.98M |
| Total assets | $1.16B | $940.38M | 405.96M | — |
| Current liabilities | $231.62M | $205.09M | 165.06M | — |
| Short-term debt | $13.11M | $11.76M | 964,000 | — |
| Long-term debt | $391.91M | $341.81M | 8.21M | — |
| Total debt | $405.02M | $353.57M | 9.17M | — |
| Total liabilities | $748.61M | $587.44M | 257.05M | — |
| Shareholders' equity | $415.38M | $352.94M | 148.91M | 80.01M |
| Net debt | $263.16M | -$86.42M | -114.06M | — |
| Cash flow statement | ||||
| Operating cash flow | -$17.29M | $27.49M | 23.88M | -63.97M |
| Capital expenditure | $25.69M | $9.12M | 9.68M | 7.04M |
| Free cash flow | -$42.98M | $18.37M | 14.21M | -71.01M |
| Investing cash flow | -$285.92M | -$86.69M | -25.49M | -17.00M |
| Financing cash flow | -$3.72M | $416.79M | 10.19M | 174.96M |
| Depreciation & amortization | $21.51M | $4.85M | 6.74M | 5.38M |
| Stock-based compensation | $19.35M | $12.93M | 8.79M | 8.11M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.